Share on LinkedInShare on LinkedIn

ARTICLE · 20 AUGUST 2026

Türkiye's Pharmaceutical Sector Under The Microscope: What The Preliminary Report Signals For Industry

Balcıoğlu Selçuk Eymirlioğlu Ardıyok Keki Attorney Partnership
Balcıoğlu Selçuk Eymirlioğlu Ardıyok Keki Attorney Partnership
Contributor
Balcıoğlu Selçuk Eymirlioğlu Ardıyok Keki Attorney Partnership

Balcıoğlu Selçuk Eymirlioğlu Ardıyok Keki Attorney Partnership

Balcıoğlu Selçuk Eymirlioğlu Ardıyok Keki Attorney Partnership (BASEAK) is an Istanbul-based...

View firm profile
Explore more from Balcıoğlu Selçuk Eymirlioğlu Ardıyok Keki Attorney Partnership

Following a sector inquiry launched by the Competition Board's decision of 8 December 2021, the Turkish Competition Authority ("TCA") published its Preliminary Report on the Pharmaceutical Sector Inquiry (“Preliminary Report”) on 10 August 2026, opening it for public consultation

TurkeyAntitrust/Competition Law

Following a sector inquiry launched by the Competition Board's decision of 8 December 2021, the Turkish Competition Authority ("TCA") published its Preliminary Report on the Pharmaceutical Sector Inquiry (“Preliminary Report”) on 10 August 2026, opening it for public consultation1. The inquiry examined the factors affecting competition throughout the process from the development of a pharmaceutical product to its distribution to patients through the retail channel, drawing on information requests to stakeholders and regulatory bodies; with on-site inspections at 16 pharmaceutical companies and input from competition authorities in various jurisdictions including Germany, France, Italy, Portugal.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from